Ashley Magargee is Chief Executive Officer of Genentech, where she leads one of the world’s most influential biotechnology organizations and its U.S. pharmaceutical operations within the Roche Group. Having joined Genentech in 2004, she has built nearly two decades of leadership experience across lifecycle management, market access, commercial portfolio strategy, and digital engagement. Prior to becoming CEO, she led Genentech’s U.S. commercial portfolio and previously served as General Manager for Roche’s commercial operations in Singapore and Brunei, giving her deep exposure to both mature and emerging oncology markets.
As CEO, Magargee’s leadership has focused on sustaining Genentech’s long-standing leadership in oncology, ensuring that scientific innovation is translated into broad clinical adoption and equitable patient access. She has overseen the alignment of commercialization strategy with Genentech’s oncology pipeline, strengthened engagement with healthcare systems, and supported investments in manufacturing and infrastructure required for complex biologics and cancer therapies. Her approach emphasizes execution, access, and durability—maintaining Genentech’s role as a central driver of oncology standards while adapting to increasingly competitive and regulated environments.
Magargee serves on the board of Pharmaceutical Research and Manufacturers of America and is a member of Roche’s Pharma Leadership Team, reflecting her influence across U.S. and global biopharma governance. Her tenure represents continuity of Genentech’s oncology-first identity, shaped through disciplined portfolio stewardship rather than short-term expansion.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Most Influential CEOs in Oncology in 2025, and stay tuned for other special category nominations.
